Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED60 Degrees Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$3.01 | -$2.61 | -$2.81 |
| Q2 2025 | 1 | -$1.26 | -$1.10 | -$1.18 |
| Q3 2025 | 1 | -$0.79 | -$0.69 | -$0.74 |
| Q4 2025 | 1 | -$0.57 | -$0.49 | -$0.53 |
60 Degrees Pharmaceuticals, Inc. Earnings Date And Information
60 Degrees Pharmaceuticals, Inc. last posted its earnings results on Wednesday, February 26th, 2025. The company reported $-4.77 earnings per share for the quarter, missing analysts' consensus estimates of $-4.01 by $0.76. The company had revenue of 135,293 for the quarter and had revenue of 253,573 for the year. 60 Degrees Pharmaceuticals, Inc. has generated $-1 earnings per share over the last year ($-0.95 diluted earnings per share) and currently has a price-to-earnings ratio of -0.54. 60 Degrees Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
60 Degrees Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$3.00 | -$0.88 | 2.12 | $250,000 | $135,293 |
| 08/14/2024 | Q2 2024 | -$19.80 | -$4.23 | 15.57 | $100,000 | $125,700 |
| 05/15/2024 | Q1 2024 | N/A | $0.04 | N/A | N/A | $146,094 |
| 04/01/2024 | Q4 2023 | -$16.21 | -$0.34 | 15.87 | N/A | $42,707 |
| 11/20/2023 | Q3 2023 | -$15.61 | $0.72 | 16.33 | $100,000 | $51,188 |
| 08/25/2023 | Q2 2023 | N/A | -$0.58 | N/A | N/A | $59,532 |
| 03/31/2023 | Q1 2023 | N/A | -$0.47 | N/A | N/A | $17,172 |
| 12/31/2022 | Q4 2022 | N/A | -$0.35 | N/A | N/A | $-75,652 |
| 09/29/2022 | Q3 2022 | N/A | -$0.26 | N/A | N/A | $168,185 |
| 06/29/2022 | Q2 2022 | N/A | -$0.39 | N/A | N/A | $45,173 |
| 03/31/2022 | Q1 2022 | N/A | -$0.16 | N/A | N/A | $47,024 |
| 12/31/2021 | Q4 2021 | N/A | -$0.23 | N/A | N/A | $29,464 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
60 Degrees Pharmaceuticals, Inc. Earnings: FAQ's
60 Degrees Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based offlast year's report dates.
The conference call for 60 Degrees Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for 60 Degrees Pharmaceuticals, Inc.'s latest earnings report can be read online.
60 Degrees Pharmaceuticals, Inc. (:SXTP) has a recorded annual revenue of $253,573.
60 Degrees Pharmaceuticals, Inc. (:SXTP) has a recorded net income of $-3,765,702.60 Degrees Pharmaceuticals, Inc. has generated $-0.95 earnings per share over the last four quarters.
60 Degrees Pharmaceuticals, Inc. (:SXTP) has a price-to-earnings ratio of -0.54 and price/earnings-to-growth ratio is 0.01.